By: Svetlana Akbasheva, Section Editor (Clinical) – Despite the advances in the treatment of human immunodeficiency virus (HIV), the incidence of HIV transmission remains alarmingly high, with about 50,000 new cases arising every year in the United States alone.1 Recently, HIV management has turned its focus on prevention for high-risk, uninfected individuals in addition to…

By: Jack (Hongkai) Bao, Staff Editor – On December 21st 2015, the FDA approved selexipag (Uptravi®), marketed by Actelion Pharmaceuticals US, Inc. for the treatment of pulmonary arterial hypertension (PAH) in adults.1 Selexipag offers a newer treatment alternative for PAH, the conventional therapy of which originally included vasodilators such as Epoprostenol (Flolan®) and Treprostinil (Remodulin®)…

By: Alex Chu, Staff Writer – On November 5th 2015, the U.S Food and Drug Administration approved Genvoya®, a once daily tablet containing a combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) for the treatment of HIV-1 infections in adults and pediatric patients age 12 or older.1 Genvoya® is a combination of antiretroviral drugs…